The use of intravenous immunoglobulin in Miller Fisher syndrome
Autor(es): Arakawa Y,Yoshimura M,Kobayashi S,Ichihashi K,Miyao M,Momoi M Y,Yanagisawa M
Resumo: We report a patient with Miller Fisher syndrome who was treated with an intravenous high-dose of immunoglobulin. This syndrome is considered to be a benign variety of acute inflammatory demyelinating polyneuropathy (Guillain-Barré syndrome). However, there have been several reports of the need for ventilatory support and a few cases have had a fatal outcome. We observed a case of progressive Miller Fisher syndrome in a 3-year-old boy. Following 2 episodes of apnea lasting about 50 s each, he was treated with intravenous immunoglobulin (400 mg/kg/day) for 5 consecutive days. His respiratory state, general muscle strength, truncal ataxia and emotional state improved remarkably after this therapy.
Palavras-Chave: Polyradiculoneuritis; Ataxia; Areflexia; Ophthalmoplegia; Miller Fisher syndrome; ApneaIntravenous immunoglobulin
Imprenta: Brain & Development, v. 15, n. 3, p. 231-233, 1993
Identificador do objeto digital: 10.1016/0387-7604(93)90071-F
Descritores: Guillain-Barre Syndrome - Proteins ; Guillain-Barre Syndrome - Antibodies ; Guillain-Barre Syndrome - Clinical examination
Data de publicação: 1993
